Press release
Economical processing and superior product safety with Alfa Laval ALTB upgraded agitator
Offering a mixing solution to meet any requirements in the hygienic industries, Alfa Laval ALTB agitator has been upgraded to provide enhanced process efficiency and product safety. The agitator, with bottom support, can be sized for almost any application in both atmospheric and pressurized tanks, providing high flexibility in mechanical design. The bottom support offers a more economical configuration with several key benefits:ADVANTAGES OF ALFA LAVAL ALTB
Lower friction, resulting in reduced wear groove and longer life-time.
Rotation independent: Safe operation with no risk of parts breaking.
Hygienic design according to EHEDG guidelines for superior product safety.
Temperature resistant up to 150°C: Less expansion, remaining tight at high temperature differences.
Improved hygienic design: Easier to install, clean, inspect and maintain. No lifting of shaft.
Energy efficient design to meet your demands
Our Alfa Laval EnSaFoil impellers, as well as our specially developed Alfa Laval EnSaFerm impellers for fermentation use, reduce energy consumption and the absorption of heat by your product. Based on extensive fluid dynamic studies, their unique shape makes them up to 400% more efficient than impellers with a standard pitch.
Besides minimizing energy loss, our impellers operate at reduced speeds without reducing pumping capacity. Compared to agitators with conventional impellers, they thereby lower agitator power consumption by up to 80%.
Agitators from Alfa Laval are designed for easy cleaning and we offer tank cleaning equipment to help you meet the stringent demands of any hygienic industry.
Configuration for use in sterile/aseptic applications is also possible. Sizing and customizing the agitator to the specific task ensures optimized power consumption and pricing
About Alfa Laval
Alfa Laval is a leading global provider of specialized products and engineering solutions based on its key technologies of heat transfer, separation and fluid handling.
The company’s equipment, systems and services are dedicated to assisting customers in optimizing the performance of their processes. The solutions help them to heat, cool, separate and transport products in industries that produce food and beverages, chemicals and petrochemicals, pharmaceuticals, starch, sugar and ethanol.
Alfa Laval’s products are also used in power plants, aboard ships, oil and gas exploration, in the mechanical engineering industry, in the mining industry and for wastewater treatment, as well as for comfort climate and refrigeration applications.
Alfa Laval's head office is:
Visiting address:
Alfa Laval Corporate AB
Rudeboksvägen 1
SE-226 55 Lund
Sweden
Tel: +46 46 36 65 00
Fax: +46 46 32 35 79
Mailing address:
Alfa Laval Corporate AB
PO Box 73
SE-221 00 Lund
Sweden
www.alfalaval.com
alfa.laval@alfalaval.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Economical processing and superior product safety with Alfa Laval ALTB upgraded agitator here
News-ID: 1053200 • Views: …
More Releases for ALTB
United States Immunology Drugs Market is to reach USD 114.60 billion by 2034 | M …
Leander, Texas- The global immunology drugs market size was US$ 122.40 Billion in 2024 and is expected to reach US$ 262.01 Billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033. Market is driven by Rising autoimmune diseases, advanced biologics, growing geriatric population, increasing healthcare spending, and innovations in targeted immunotherapies drive growth
Download Free sample report:-https://www.datamintelligence.com/download-sample/immunology-drugs-market?pratik
Recent Industry Development in U.S market:
✅ The U.S. immunology drugs…
Ulcerative Colitis Clinical Trials Analysis 2025: Advancing Biologics, Small Mol …
DelveInsight's "Ulcerative Colitis - Clinical Trials Analysis, 2025" reviews the expanding landscape of therapies in development for ulcerative colitis (UC), a chronic inflammatory bowel disease that continues to impose substantial morbidity worldwide. While anti-TNF biologics, JAK inhibitors, and S1P modulators have reshaped treatment in recent years, many patients with moderate-to-severe UC remain refractory, underscoring persistent unmet needs.
The UC clinical trial space is rapidly evolving, with next-generation IL-23 and TYK2 inhibitors,…
Graft Versus Host Disease Market Expected to rise, 2034 | Biocon, medac GmbH, Ma …
The Graft Versus Host Disease market growth is driven by factors like increase in the prevalence of Graft Versus Host Disease, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Graft Versus Host Disease market report [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Graft Versus Host Disease market size, share, Graft Versus Host Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key…
Graft Versus Host Disease Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Graft versus host disease Pipeline Insight 2024" report provides comprehensive insights about 60+ GvHD companies and 65+ pipeline drugs in Graft versus host disease (GVHD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Graft…
Graft Versus Host Disease Pipeline, FDA Approvals, Unmet Needs, Preclinical and …
DelveInsight's, "Graft versus host disease Pipeline Insight 2024" report provides comprehensive insights about 60+ GvHD companies and 65+ pipeline drugs in Graft versus host disease (GVHD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Graft…
Graft versus Host Disease Pipeline, FDA Approvals, Unmet Needs, Preclinical and …
DelveInsight's, "Graft versus Host Disease Pipeline Insight 2024" report provides comprehensive insights about 60+ Graft versus Host Disease companies and 65+ pipeline drugs in Graft versus Host Disease pipeline landscape. It covers the Graft versus Host Disease pipeline drug profiles, including clinical and nonclinical stage products. Graft versus Host Disease pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights…